However, future additional experimental validation of CSF2 and its regulation, as well as proper exclusion of IL-13 and TSLP in the effects of NCTD on CRC or other types of tumor cells may provide further insights into the particular anticancer mechanism of NCTD. This evidence concerns the gene IL13 and colorectal carcinoma.